Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Akero Therapeutics
Biotech
As Madrigal lands MASH nod, what's next for biotechs in pursuit?
Madrigal’s MASH drug has been approved. For the other companies with up-and-coming treatments trailing in the clinic, the question is: What now?
Annalee Armstrong
Mar 15, 2024 10:55am
Akero soars as liver scarring improves in longer MASH trial
Mar 4, 2024 6:30am
Akero's NASH miss drags a few peers down, spurring deja vu
Oct 11, 2023 10:50am
Akero sinks as midphase cirrhosis fail sparks flash NASH crash
Oct 10, 2023 8:00am
Ex-Novartis drug clears NASH test, fueling pursuit of Akero
Jun 21, 2023 7:15am
Akero reduces liver fat in NASH-diabetes drug combo cohort
Jun 5, 2023 7:00am
